OVERVIEW OF ACTIVITY

Breast cancer is one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic/prognostic tools. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Integrate validated genomic assays into the clinical management of hormone receptor (HR)-positive, node-negative or node-positive early breast cancer.
• Apply the results of recent clinical trials when recommending aromatase inhibitors and/or tamoxifen as primary therapy for postmenopausal women with HR-positive early breast cancer.
• Formulate an evidence-based algorithm for the treatment of localized or metastatic, HER2-positive breast cancer.
• Demonstrate knowledge of ongoing investigational approaches to the management of triple-negative or HER2-positive breast cancer.
• Compare and contrast the efficacy, safety and individualized utility of anthracycline- and nonanthracycline-based adjuvant chemotherapy regimens.
• Consider the unique benefits and risks associated with novel epothilones and taxanes when selecting and sequencing chemotherapeutic regimens.
• Recall emerging clinical trial results with bevacizumab for metastatic breast cancer, and assess their application to current patient care.
• Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should review the CME information, listen to the CDs and complete the Post-test and Educational Assessment and Credit Form located on our website at ResearchToPractice.com/BCU.

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Ortho Biotech Products LP, Roche Laboratories Inc and Sanofi-Aventis.

Home · Search

EDITOR
Neil Love, MD

INTERVIEWS

Harold J Burstein, MD, PhD
- Select publications

Jack Cuzick, PhD
- Select publications

Howard A Burris III, MD
- Select publications

Mark D Pegram, MD
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office